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ABSTRACT The study aim was to image severe alcoholic hepatitis (SAH) using 
111In-labelled leucocytes with two objectives in mind: firstly for non-invasive 
diagnosis and secondly to provide a platform for experimental therapies aiming to 
inhibit intrahepatic neutrophil migration.  111In-leucocyte scintigraphy was performed 
30 min and 24 h post-injection in 19 patients with SAH, 14 abstinent patients with 
alcohol-related cirrhosis and 11 normal controls. Eleven with SAH and 7 with 
cirrhosis also had 99mTc-nanocolloid scintigraphy. Change in hepatic 111In 
radioactivity was expressed as decay-corrected 24 h:30 min count ratio and, in SAH, 
compared with histological grading of steatohepatitis and expression of granulocyte 
marker, CD15.  Hepatic microautoradiography on biopsy specimens obtained 24 h 
post-injection of 111In-leucocytes was performed in one patient. Median 24 h:30 min 
hepatic 111In activity ratio was higher in SAH (2.5 [IQR 1.7-4.0] compared with 
cirrhotics and normal controls (1.0 [0.8-1.1] and 0.8 [0.7-0.9] respectively, 
P<0.0001). In SAH, it correlated with CD15 expression (r=0.62, P=0.023) and was 
higher in marked versus mild/moderate steatohepatitis (4.0 [3.0-4.6] versus 1.8 [1.5-
2.6], P=0.006). Hepatic-to-splenic 99mTc count rate ratio was reduced in SAH (0.5 
[0.4-1.4]) compared with cirrhotics (2.3 [0.6-3.0]) and 3 historic normal controls (4.2 
[3.8-5.0]; P=0.003), consistent with impaired hepatic reticuloendothelial function. 
Scintigraphic findings in SAH included prominent lung radioactivity at 30 min, likely 
the result of neutrophil primimg. Microautoradiography demonstrated cell-associated 
111In in areas of parenchymal neutrophil infiltration. In conclusion, 111In-leucocyte 
scintigraphy can non-invasively diagnose SAH and could provide a platform for 
evaluation of novel treatments aiming to inhibit intrahepatic neutrophil migration. 
 
 3 
Key words: alcohol-related liver disease; cirrhosis; 111In-labelled leucocytes; liver 
biopsy; inflammation 
 
List of abbreviations: ALP alkaline phosphatase, ALT alanine aminotransferase, 
ARLD alcohol-related liver disease, AST aspartate aminotransferase, CS 
corticosteroids, DF discriminant function, ECBL early change in bilirubin level, 
GAHS Glasgow alcoholic hepatitis score, GI gastrointestinal, γGT Gamma glutamyl 
transpeptidase, HE hepatic encephalopathy, HRS hepatorenal syndrome, INR 
international normalised ratio, IQR interquartile range, MELD model for end-stage 
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INTRODUCTION 
Alcohol-related liver disease (ARLD) is a growing clinical problem. In the UK, rates 
of hospitalisation and death have risen by almost 50% over the past decade, a trend 
which is projected to continue (1). Acute alcoholic hepatitis (AH) is the most florid 
form of alcohol-related liver disease (ARLD). It presents with jaundice and systemic 
upset in heavy drinkers. Clinically mild AH may resolve with abstinence but in-
hospital mortality in severe AH (SAH), defined by a discriminant function (DF) ≥32, 
approaches 40% (2). Prompt diagnosis is key to improving survival, enabling timely 
supportive care, nutritional support and potentially specific medical therapies such as 
corticosteroids (3). Although histology is the gold standard for diagnosing SAH, liver 
biopsy is controversial because its accuracy varies from 50-90% (4–6).  In most 
instances, coagulopathy and ascites mandate transjugular biopsy (TJB), an invasive 
procedure with recognised morbidity and mortality (7). Histological features include a 
neutrophil-rich parenchymal inflammatory infiltrate surrounding ballooned 
hepatocytes, often with eosinophilic Mallory-Denk inclusion bodies (8). Biopsy may 
yield prognostic information; for example, neutrophil infiltration correlates positively 
with corticosteroid response (9) and short-term survival (10).  Doppler 
ultrasonography and scintigraphy with 99mTc-colloids (11,12) may support the 
diagnosis but lack specificity. There is therefore a recognised need for non-invasive 
diagnostic tests (3). 
 
The predominating inflammatory cell infiltrating the liver in SAH is the neutrophil 
(8). Almost all inflammatory diseases involving neutrophils have been imaged at 
some time with radiolabelled leucocytes, most notably inflammatory bowel disease in 
a gastroenterological context (13). The labelled neutrophil is the effective ingredient 
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in labelled leucocytes, which therefore depict not only neutrophil-predominant 
inflammation but also physiological neutrophil kinetics, especially neutrophil transit 
through the lungs (14), pooling (i.e. slow intravascular transit) in tissues (specifically, 
liver, spleen and bone marrow) (15), and sites of physiological neutrophil destruction 
(again, liver, spleen and bone marrow) (16).  Despite their widespread use in other 
scenarios, labelled leucocytes have never previously been used to diagnose hepatic 
inflammation, probably because the liver is a major site of physiological neutrophil 
pooling and destruction, and consequently regarded as beyond such inflammation-
targeted imaging.  
 
In SAH, however, we speculated that physiological neutrophil pooling and 
destruction would be sufficiently impaired to expose pathological neutrophil 
migration in the liver and thereby allow imaging of inflammation with labelled 
leucocytes or purified neutrophils. This would open up two potentially important 
applications: firstly, diagnosing SAH non-invasively in the appropriate clinical 
setting, and secondly providing a platform for testing new anti-inflammatory 
therapies, analogous to the use of 111In-labelled neutrophils and eosinophils in 
inflammatory lung disease (17,18). The aim of the current study, therefore, was to 
investigate the potential of 111In-labelled leucocytes to non-invasively image SAH. 
 
METHODS 
This was a prospective study involving 3 groups of patients.  
1. Subjects with SAH (n=19) who were recruited from consecutive hospital 
admissions. SAH was suspected on clinical grounds from an admission DF ≥32 in 
active or recently abstinent heavy alcohol consumers with jaundice for ≤3 months, 
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and confirmed wherever possible by TJB. All patients were screened to exclude other 
causes of liver disease, co-existent biliary obstruction and focal hepatic lesions. 
Medical therapy for SAH with corticosteroids (prednisolone 40 mg daily) and/or 
pentoxifylline (1200 mg daily) was prescribed at the discretion of the managing 
hepatologist. The response to treatment was determined by a fall in bilirubin level 
following a week of therapy (19). Two patients received no specific treatment for 
SAH and 3 were given blinded therapy as part of another placebo-controlled study 
(20), preventing assessment of treatment response. Therapy was started after imaging 
in 5 patients, while in the remaining 9 the median duration of treatment at the time of 
scintigraphy was 2 [1.5-6.5] days. 
 
2. Patients with alcohol-related cirrhosis but without SAH (n=14) who were recruited 
following abstinence from alcohol for ≥6 months to ensure resolution of subclinical 
steatohepatitis. Cirrhosis was diagnosed from the combination of cutaneous stigmata 
of chronic liver disease, radiological findings (irregular liver margin with or without 
splenomegaly) and corroborative histology, where available. 
 
3. Controls without liver disease (n=11) who were referred for 111In-leucocyte 
scintigraphy for suspected prosthetic joint infection. They had normal liver 
biochemistry, no risk factors for liver disease and no evidence of inflammatory 
pathology on 111In-leucocyte scintigraphy, so could be regarded as normal controls. 
Those reporting alcohol use exceeding Royal College of Physicians guidelines on safe 
consumption were excluded. The study received ethical approval via the NHS 
National Research Ethics Service. (Reference Number 08/H1107/36). 
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Leucocyte labelling  
Autologous leucocytes from peripheral venous blood were labelled in vitro under 
sterile conditions with the lipophilic chelating agents, 111In-oxine (n = 41) or 111In-
tropolonate (n = 3, all with SAH) according to published guidelines (21). Briefly, 
erythrocytes were allowed to sediment from 35 ml anticoagulated blood, aided by the 
addition of 1% methylcellulose. A leucocyte-rich, platelet-deplete cell pellet was 
obtained by centrifugation of the supernatant. The cells were re-suspended in saline 
(111In-oxine) or plasma (111In-tropolonate) and incubated with approximately 25 MBq 
of 111In-chelate for 15 min, before addition of autologous platelet-poor plasma. The 
labelled leucocytes were pelleted, supernatant aspirated, and cell-associated and 
unbound radioactivity measured to calculate labelling efficiency. 111In-labelled 
leucocytes were re-suspended in a further 3 ml of platelet-poor plasma and injected 
intravenously. The administered radioactivity was ~20 MBq, giving a radiation 
exposure of ~7 mSv.  
 
111In-leucocyte imaging protocol 
Static planar images of the chest and abdomen were obtained 30 min and 24 h after 
administration of labelled leucocytes using a dual-headed gamma camera (SMV 
DSTXL or GE Discovery NM630) with medium energy collimators and a 10-min 
acquisition time. To assess labelled cell viability, the recovery of cell-bound label was 
determined from peripheral venous blood samples obtained 45 min post-injection and 
expressed as a percentage of administered activity. 
 
111In-leucocyte image analysis 
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Tissue-associated radioactivity (expressed as mean counts per pixel) was determined 
from manually defined regions of interest (ROI) over homogeneous areas of liver, 
spleen and lungs. The geometric mean of anterior and posterior counts was corrected 
for physical radionuclide decay and background activity. The change in liver-
associated radioactivity between the two imaging times was expressed as the 24 h:30 
min ratio of activities.  
 
99mTc-nanocolloid scintigraphy 
99mTc-nanocolloid scintigraphy was performed after completion of 111In-leucocyte 
scintigraphy in 11 patients with SAH and 7 abstinent patients with cirrhosis. 
Abdominal gamma camera images (SMV DSTXL) were acquired 20 min post-
injection of 80 MBq 99mTc-nanocolloid (Nanocoll, GE Healthcare, Amersham, UK; 
radiation exposure ~1 mSv) using low-energy high-resolution collimation. Down-
scatter from the 111In photopeak accounted for <15% of 99mTc tissue activity. 
Geometric means of counts per pixel were calculated for liver and spleen in the same 
ROI as above and expressed as liver:spleen ratio. 
 
Liver biopsy 
TJB (radiation exposure ~10 mSv) was performed in patients with SAH within 1 
week of 111In-leucocyte scintigraphy. Independent biopsy interpretation was 
undertaken by two histopathologists blinded to the other’s findings and to 
scintigraphy. SAH was defined as the coexistence of steatosis, hepatocyte ballooning 
and lobular neutrophil infiltration (3). Histological features of steatohepatitis, 
including hepatocyte ballooning, lobular inflammation, steatosis, canalicular 
cholestasis, ductular cholestasis and cholangiolitis, were assessed according to 
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recently described criteria (4). The severity of steatohepatitis was semi-quantitatively 
classified as mild, moderate or marked according to whether foci of infiltrating 
parenchymal neutrophils were sparse, moderate or abundant.  Cells positive for 
granulocyte marker CD15 were counted in 5-10 non-consecutive high-power fields in 
13 patients in whom sufficient biopsy material was available for 
immunohistochemical staining, and the median count averaged between the two 
histopathologists.  
 
Microautoradiography 
To determine the intrahepatic fate of 111In-leucocytes in SAH, microautoradiography 
was performed on biopsy specimens obtained 24 h post-injection of labelled 
leucocytes in a single patient. Formalin-fixed liver sections (3 µm thickness) were 
placed on positively charged adhesive slides, de-waxed and a radiosensitive emulsion 
(Ilford K2, Harman Technology, UK) applied in dark room conditions. Micro-
autoradiographs were exposed in dry, dark conditions for two weeks, following which 
they were fixed, developed, dried, post-stained with H&E and inspected for foci of 
radioactivity. 
 
Statistical analysis 
Data are presented as mean ± standard deviation or median [interquartile range]. 
Parametric data were compared using Student’s t-test or analysis of variance 
(ANOVA) and non-parametric data using Mann-Whitney U or Kruskal-Wallis tests. 
Correlation was quantified using Pearson’s correlation coefficient (r) or Spearman’s 
rho (ρ) for parametric and non-parametric data, respectively. Inter-observer agreement 
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of categorical histopathology data was assessed using the kappa statistic (κ). Reported 
P values are two-tailed. 
 
RESULTS 
Patients 
Baseline characteristics and demographic data are shown in Table 1. Median alcohol 
consumption prior to admission was 144 g/day [80-200] for 10 [5-15] years. Four 
abstinent cirrhotics had histologically confirmed disease. The diagnosis in the 
remaining 7 rested on clinical and radiological grounds. 
 
In patients with SAH, the median admission DF was 52 [44-75]; the Glasgow 
Alcoholic Hepatitis Score (GAHS) (22) was ≥9 in 12 and Modified End-stage Liver 
Disease (MELD) (23) score ≥21 in 16. Four (21%) had evidence of the systemic 
inflammatory response syndrome and two had active infection (limb cellulitis and 
spontaneous bacterial peritonitis). Peripheral blood leucocyte counts were 
significantly higher in SAH than in either of the other groups (Table 1; P<0.001). 
Normal controls were significantly older than either cohort with liver disease (P = 
0.009), consistent with the population referred for investigation of prosthetic joint 
pain. 
 
111In-labelled-leucocyte scintigraphy 
Labelling efficiency was broadly similar between the 3 patient groups: 89 (85-92)%, 
84 (81-85)% and 86 (81-88)%. Labelled cell recovery, however, was significantly 
higher in SAH (57 [48-63]%) compared with abstinent cirrhotics and normal controls 
(38 [26-46]% and 38 [34-44]%, respectively, P = 0.002),  
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Normal 111In-leucocyte scintigraphy 30 min post-injection shows prominent activity 
in liver and spleen, and faint diffuse activity in the lungs. At 24 h, the diffuse lung 
activity disappears and bone marrow activity becomes evident (Fig 1). Liver activity 
falls slightly while spleen remains largely unchanged, suggesting that leucocyte 
pooling is broadly matched by neutrophil destruction (13). 
 
The 24 h:30 min activity ratio in the liver was significantly higher in SAH (2.5 [1.7-
4.0] compared with abstinent cirrhotics (1.0 [0.8-1.1]) and controls (0.8 [0.7-0.9], P < 
0.0001; Figs 2 and 3). Scintigraphic appearances in SAH were similar between 111In-
oxine and 111In-tropolone radiolabelling (Fig 2). Two abstinent cirrhotics had 
decompensated liver disease with diuretic-refractory ascites and liver synthetic 
impairment (both Child-Pugh class B). The 24 h:30 min ratio in these two individuals 
(1.08 and 1.37) was not significantly higher than in compensated cirrhosis (median 
0.96 [0.78-0.99], P = 0.067) and remained substantially lower than the cohort with 
SAH (P = 0.025). 
 
Prominent diffuse pulmonary activity at 30 min, which cleared by 24 h, was a 
frequent finding in SAH (Fig 2) and occurred to a lesser degree in abstinent cirrhotics. 
Median lung-associated radioactivity at 30 min (expressed relative to splenic activity) 
was significantly higher in SAH (20 [15-26]%) than normal controls (14.5 [13-16]%; 
P = 0.02), but did not differ significantly from abstinent cirrhotics (18 [12.5-25]%, P 
= 0.38). By 24 h, lung radioactivity had decreased similarly in all 3 groups but could 
not be quantified because of overlying physiological activity in chest wall bone 
marrow.  
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Abnormal gut-associated radioactivity 24 h post-injection was observed in 4 patients 
with SAH (Fig 2). Delayed imaging at 48-72 h demonstrated distal transit of 111In 
within bowel, in keeping with access of labelled leucocytes into bowel. 
 
Liver histology in SAH 
Clinical deterioration after 111In-leucocyte scintigraphy precluded TJB in 2 patients 
with SAH, leaving 17 with histology. The majority had underlying advanced hepatic 
fibrosis or cirrhosis and all exhibited some degree of steatohepatitis, judged to be 
marked in 7 (Table 2). Inter-observer agreement of fibrosis stage, steatosis grade, 
steatohepatitis severity and presence of Mallory’s hyaline was high (κ≥0.5), but there 
was substantial variability in assessment of ballooning grade, degree of canalicular 
cholestasis and the presence of cholangiolitis and Councilman bodies (κ≤0.2 in all). 
 
There was agreement between histopathologists regarding severity of parenchymal 
neutrophil infiltration in 16 of 17 patients. Steatohepatitis was deemed marked in 7 
patients, moderate in 7 and mild in 2. The 24 h:30 min hepatic activity ratio was 
significantly higher in marked steatohepatitis (4.0 [3.0-4.6]) compared with moderate 
(1.9 [1.6-3.0]) and mild (1.45 [1.2-1.7]) steatohepatitis (P = 0.022; Fig 4). The 24 
h:30 min ratio in patients with histologically mild steatohepatitis was similar to that in 
abstinent cirrhotics with hepatic decompensation (P = 0.25).  
 
There was good inter-observer agreement in parenchymal granulocyte quantification 
determined from CD15-positive cell counts (r = 0.85, P<0.001). CD15-positivity 
count correlated modestly with the 24 h:30 min ratio (Fig 4; r = 0.62; P = 0.023). 
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Examples of 111In-leucocyte scintigraphy and corresponding liver biopsy sections in 
mild versus marked steatohepatitis are shown in Fig 5. No association was observed 
between the 24 h:30 min activity ratio and fibrosis stage. 
 
Clinical parameters, treatment response and survival 
There was no correlation between the 24 h:30 min activity ratio and serum bilirubin (ρ 
= 0.02, P = 0.9), peripheral blood leukocyte counts (ρ = 0.28, P = 0.25) or clinical 
measures of disease severity, including Child-Pugh score (ρ = -0.17, P = 0.5), DF (ρ = 
0.16, P = 0.5), GAHS (ρ = 0.29, P = 0.23) or MELD (ρ = 0.26, P = 0.29). Assessment 
of treatment response in SAH was precluded in 3 patients who were treated as part of 
another placebo-controlled trial. Of the remaining 16, 14 received corticosteroids 
and/or pentoxifylline, of whom 10 exhibited a clinical response following a week of 
therapy. No significant difference was observed in the 24 h:30 min activity ratio 
between patients who responded to therapy compared with non-responders (2.4 [1.6-
3.8] versus 2.3 [1.7-2.6]). Inpatient mortality (21%) was not predicted by imaging 
findings. Furthermore, there was no association between histological findings and 
either treatment response or in-hospital survival.  
 
Microautoradiography 
H&E stained autoradiography undertaken in one patient with SAH demonstrated foci 
of cell-associated radioactivity in areas of parenchymal neutrophil infiltration with 
low level background hepatic radioactivity (Fig 6). The 24 h:30 min hepatic activity 
ratio in this patient was 4.5. 
 
 14 
99mTc-nanocolloid scintigraphy 
Hepatic-to-splenic uptake ratio of 99mTc-nanocolloid was significantly lower in SAH 
(median 0.5 [0.4-1.4]) compared with abstinent cirrhotics (2.3 [0.6-3.0]) and 3 historic 
controls without liver disease (4.2 [3.8-5.0]; P = 0.003; Fig 7). In SAH patients, 
however, there was no correlation between 99mTc-nanocolloid liver/spleen ratios and 
either the 24 h:30 min activity ratio (r =  -0.04, P = 0.9) or histological severity of 
steatohepatitis (r = -0.4, P = 0.3). 
 
DISCUSSION 
This proof-of-concept study shows for the first time that hepatic neutrophil migration 
can be successfully imaged and semi-quantified using 111In-leucocyte scintigraphy. 
This provides not only a potential means of diagnosis and outcome prediction in 
SAH, but also, importantly, a platform for the assessment of new anti-inflammatory 
therapies for a range of acute inflammatory liver disorders.  An analogous scenario is 
inflammatory pulmonary disease in which there is interest in using labelled 
neutrophils and eosinophils for assessing new therapies. Whilst labelled ‘mixed’ 
leucocytes are shown here to be appropriate for routine clinical use, labelled purified 
neutrophils would probably be preferable for research applications.  
 
Current European guidelines recognise the need for non-invasive diagnostic tools for 
SAH (3). Abnormal leucocyte scintigraphy in SAH was characterised by an increase 
in liver-associated radioactivity between 30 min and 24 h, not seen in abstinent 
cirrhotics or normal controls. The 24 h:30 min hepatic activity ratio portrays 
intrahepatic neutrophil migration as shown by correlation with measures of neutrophil 
infiltration on liver biopsy.  
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We hypothesised that, for whatever mechanistic reason but almost certainly including 
reduced hepatic blood flow, physiological hepatic accumulation of 111In, both at 30 
min as a result of impaired pooling, and 24 h as a result of impaired destruction, 
would be sufficiently decreased in SAH to expose hepatic neutrophil migration as an 
increase in liver-associated radioactivity between 30 min and 24 h. Consistent with 
impaired neutrophil destruction, hepatic accumulation of 99mTc-nanocolloid was 
suppressed in SAH (Fig 7), corroborating the findings of earlier studies indicating 
impaired Kupffer cell phagocytic function (12,24). The increase in liver-associated 
111In activity is almost certainly, therefore, the result of neutrophil migration. This 
interpretation is supported by microautoradiography of biopsy material obtained 24 h 
post-injection of 111In-leucocytes, which demonstrated, albeit in only one individual, 
discrete foci of cell-associated radioactivity in areas of neutrophil satellitosis within 
the lobular parenchyma. Moreover, although it provides no insight into the 
mechanisms of cellular extravasation, CD15 expression correlated significantly with 
the 24 h:30 min activity ratio. 
 
Several extrahepatic features were noted on 111In-leucocyte scintigraphy. Prominent 
diffuse lung radioactivity at 30 min, clearing by 24 h, was a consistent finding in 
SAH, suggesting pulmonary vascular entrapment of primed neutrophils without 
extravascular migration. These imaging features have been reported in several other 
disorders associated with systemic neutrophil priming, including vasculitis (25) and 
severe inflammatory bowel disease (26). Leucocyte kinetics associated with priming 
are different from those seen following labelling-induced leucocyte injury, which 
gives immediate lung activity, markedly reduced 45 min recovery and decreased 
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physiological uptake in the spleen and bone marrow. Our scintigraphic findings of 
priming add to the existing ex vivo evidence for systemic neutrophil priming in SAH 
(27) and suggest that priming also occurs, albeit to a lesser degree, in patients with 
compensated chronic liver disease.  
 
Labelled leucocyte recovery is probably the best benchmark of cell ‘health’ following 
labelling. The marginated neutrophil pool (which in health resides in the liver, spleen 
and bone marrow) (16) is in equilibrium with the circulating pool, and represents 
approximately 50% of the total blood neutrophil pool. Maximum recovery is therefore 
~50% of administered activity. The increased recovery in SAH, despite increased 
pulmonary margination, suggests a pathophysiological shift in granulocyte 
margination away from the liver, in keeping with clearly reduced hepatic activity at 
30 min post-injection in SAH (Fig 2). On the other hand, delayed pulmonary transit 
would be expected to reduce recovery. 
 
Abnormal gut radioactivity was observed in a fifth of patients with SAH, in the 
absence of gastrointestinal symptoms or apparent disease. Because ‘free’ 111In does 
not enter the gut, distal transit of 111In on delayed imaging suggests luminal transit of 
labelled cells within faeces. The cause remains unclear and warrants further study, 
although potential explanations include disposal of intrahepatic neutrophils cells via 
bile, or more likely a sequel of portal hypertension. 
 
We did not identify patients with clinically suspected SAH where histology refuted or 
altered the diagnosis, as others have shown (4,6). Our data, however, demonstrated 
significant heterogeneity in the severity of steatohepatitis that was independent of 
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clinical and laboratory disease markers, but predicted by 111In-leucocyte scintigraphy. 
No correlation was observed between clinical prognostic scores commonly used to 
judge disease severity and either the 24:30 min activity ratio or histological severity 
of steatohepatitis. However, most patients had clinically advanced disease making it 
difficult to further stratify according to disease severity. 
 
Although recent clinical trials have questioned the benefit from corticosteroids (20), 
they remain widely used in medical management of SAH. Previous authors described 
a positive association between parenchymal neutrophil infiltration and clinical 
corticosteroid response in SAH (9). Predicting response to therapy would be useful, 
particularly given the high rates of infection and poor survival in corticosteroid non-
responders (28). We did not demonstrate a relationship between scintigraphic findings 
and either treatment response or in-hospital mortality. Furthermore, we saw no 
association between steatohepatitis severity and either treatment response or survival, 
probably because of heterogeneity in prescribed therapies and small patient numbers. 
A larger study, powered to assess these specific end points, would be required to 
assess the prognostic value of 111In-leucocyte scintigraphy. 
 
Further study limitations are as follows. For the convenience that would be important 
in routine clinical studies, we used labelled ‘mixed’ leucocytes. However, although 
mixed leucocytes clearly demonstrate the feasibility of imaging hepatic inflammation, 
111In-labelled purified neutrophils would be preferable for research applications. 111In 
is preferable to 99mTc because of its greater cell labelling stability. Moreover, 111In 
preferentially labels neutrophils, unlike 99mTc-hexamethylpropylamine oxime 
(HMPAO), which is strongly selective for eosinophils (29).  
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Differentiation of SAH from other acute deteriorations of chronic liver disease, 
particularly end-stage cirrhosis or decompensation due to infection, is often 
challenging and any non-invasive diagnostic test for SAH would need to distinguish it 
from decompensation. Although they will form the cohort for future studies, we did 
not include a control group with decompensated cirrhosis at this stage of our work as 
our primary aim was to establish the feasibility of imaging hepatic inflammation with 
radiolabelled leucocytes in homogeneous patient cohorts. A decompensated group 
would be highly heterogenous and likely to include patients with ongoing or recent 
alcohol use, in whom subclinical alcoholic hepatitis would be a significant 
unmeasured confounder.  Confident inclusion of such patients, moreover, would have 
required TJB for the sole purpose of excluding those with histologically active 
steatohepatitis, and would therefore have raised significant ethical issues. TJB in 
SAH, in contrast, is clinically justifiable and indeed standard of care in some centres. 
Liver biopsy is not common practice in other forms of ARLD, which are invariably 
associated with ongoing alcohol use. Given their high prevalence of asymptomatic 
subclinical steatohepatitis, active heavy drinkers [30], other than SAH patients, were 
not included. Patients with cirrhosis were therefore recruited following at least 6 
month’s abstinence, to allow sufficient time for resolution of underlying 
steatohepatitis.  
 
In conclusion, we have demonstrated how 111In-labelled leucocyte scintigraphy can be 
exploited to detect hepatic neutrophil migration in SAH. The technique has potential 
clinical application as a non-invasive means of diagnosing this condition and 
assessing the severity of liver inflammation without the need for liver biopsy. 
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Importantly, it also has the potential to provide a platform for experimental therapies 
aiming to inhibit intrahepatic neutrophil migration. Evaluation of leucocyte kinetics in 
other forms of acute and acute-on-chronic liver disease would be of interest. 
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Table 1. Demographics and patient characteristics at recruitment 
 Severe AH (n=19) 
Abstinent 
cirrhosis 
(n=14) 
Normal controls 
(n=11) P 
Age (years) 50.3 ±9.8 55.7 ±8.9 64.0 ±14.9* 0.009 
Male gender 14 (73.7%) 11 (78.6%) 7 (63.6%) 0.702 
Ascites 11 (57.9%)* 2 (14.3%) - 0.015 
SIRS 4 (21.1%) - -  
Child-Pugh Score 10 (8-11)* 5 (5-6) - <0.0001 
MELD score 23 (22-27)* 8.8 (7.4-9.3) - <0.0001 
DF 52 (44-75) - - - 
GAHS 9 (8-10) - - - 
GAHS ≥9 12 (63.2%) - - - 
Leukocyte count 
(x109/l) 12.6 (9.3-15.9)* 6.6 (5.6-7.6) 7.0 (6.3-8.7) <0.001 
Neutrophil count 
(x109/l) 9.8 (7.1-13.3)* 3.9 (2.6-4.9) 4.3 (3.7-5.5) <0.001 
Platelet count (x109/l) 158 (106-264) 136 (91-194)* 239 (174-287) 0.047 
INR 1.8 (1.6-2.1)* 1.1 (1.1-1.2) 1.1 (1.0-1.1) <0.0001 
Bilirubin (µmol/l) 288 (202-451)* 10 (8-17) 7 (4-11) <0.0001 
Albumin (g/l) 29 (27-34)* 43.5 (37-46) 43 (42-44) <0.0001 
Creatinine (µmol/l) 56 (47-102) 80.5 (62-107) 78 (58-81) 0.085 
ALT (U/l) 63 (49-80)* 17.5 (15-32) 20 (15-22) <0.0001 
AST (U/l) 171 (117-220)* 36.5 (25-46) 18 (14-20) <0.0001 
Data are presented as mean ±standard deviation, median (IQR) or number (%), *P <0.05 
SIRS: ≥2 features of the systemic inflammatory response syndrome at recruitment, MELD: 
Modified end-stage liver disease score, DF: Discriminant function, GAHS: Glasgow Alcoholic 
Hepatitis Score, INR: international normalised ratio, ALT: alanine aminotransferase, AST: 
aspartate aminotransferase 
Normal values: bilirubin 0-21 µmol/l, INR 0.8-1.2, albumin 35-52g/l, ALP 40-129 iu/l, ALT 0-
41 iu/l, AST 0-40 iu/l, γGT 10-71 iu/l, urea 1.7-8.3 mmol/l, creatinine 62-106 µmol/l, 
leukocyte count 4-11 x109/l, neutrophil count 2-7.5 x109/l, platelet count 150-450 109/l 
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Table 2. Summary of dual histopathologist liver biopsy interpretation in severe AH (n=17) 
Histological parameter Pathologist #1  n (%) 
Pathologist #2 
n (%) 
Agreement κ 
(P) 
Ishak fibrosis stage    
Cirrhosis 9 (52.9%) 10 (58.8%) 0.538 
Stage 5 7 (41.2%) 2 (11.8%) (P <0.0001) 
Stage 4 - 1 (5.9%)  
Stage 3 - 3 (17.6%)  
Stage 2 1 (5.9%) 1 (5.9%)  
Steatosis (parenchymal involvement)    
<5% 1 (5.9%) 2 (11.8%) 0.750 
5-33% 6 (35.3%) 6 (35.3%) (P <0.0001) 
>33-66% 7 (41.2%) 5 (29.4%)  
>66% 3 (17.6%) 4 (23.5%)  
Severity of lobular neutrophil infiltrate    
Minimal 2 (11.8%) 3 (17.6%) 0.904 
Moderate 8 (47.1%) 7 (41.2%) (P <0.0001) 
Marked 7 (41.2%) 7 (41.2%)  
Parenchymal involvement by ballooning    
No ballooning - -  
<5% 1 (5.9%) 2 (11.8%) 0.183 
>5-10% 1 (5.9%) 4 (23.5%) (P =0.160) 
>10-20% 6 (35.3%) 3 (17.6%)  
>20-50% 8 (47.1%) 7 (41.2%)  
>50% 1 (5.9%) 1 (5.9%)  
Canalicular cholestasis 
      
   
None 5 (29.4%) 5 (29.4%) 0.174 
<5 - 9 (52.9%) (P =0.033) 
>5-10 1 (5.9%) 1 (5.9%)  
>10-20 8 (47.1%) 2 (11.8%)  
>20 3 (17.6%) -  
Ductular cholestasis 
      
   
None 14 (82.4%) 14 (82.4%) 0.218 
1 2 (11.8%) 3 (17.6%) (P = 0.285) 
2 - -  
3 - -  
>3 1 (5.9%) -  
Mallory’s hyaline 14 (82.4%) 15 (88.2%) 0.767 (P = 0.001) 
Cholangiolitis 
Polymorphs around & in ductule lumen 13 (76.5%) 12 (70.6%) 
-0.053 
(P = 0.825) 
Councilman bodies 9 (47.1%) 4 (23.5%) 0.029 (P = 0.893) 
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Figure Legends 
Fig 1. Gamma camera images (anterior and posterior projections) obtained 30 min 
and 24 h after injection of autologous 111In-labelled leucocytes in a control patient. 
Liver: open arrows; spleen: closed arrows. Hepatic and splenic activities reflect 
physiological leucocyte pooling at 30 min and cell destruction at 24 h. Hepatic 
activity remains unchanged or decreases between the two time points. Lung activity 
can be seen faintly at 30 min. 
 
Fig 2. Anterior gamma camera images following 111In-leucocyte administration with 
corresponding 24 h:30 min hepatic activity ratios in a control patient (a), abstinent 
alcohol-related cirrhotic patient (b), and patients with SAH using 111In-oxine labelling 
(c) and 111In-tropolonate  labelling (d). Extrahepatic findings in SAH included 
prominent lung activity at 30 min post-injection (arrows) and gut activity at 24 h 
(circled) (e). 
 
Fig 3. The 24 h:30 min hepatic activity ratio in patients with SAH, abstinent cirrhotics 
and normal controls (bars depict median value, whiskers show IQR). The 24 h:30 min 
ratios were significantly higher in SAH. 
 
Fig 4. Comparison between 111In-leucocyte scintigraphy and histology in SAH. The 
24 h:30 min hepatic activity ratios were significantly higher in marked versus mild 
and moderate steatohepatitis [pathologist #1 (a) and pathologist #2 (b)]. CD15 
quantification of parenchymal neutrophil infiltration correlated with 24 h:30 min 
activity ratio (c). 
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Fig 5.  111In-leucocyte scintigraphy in patients with mild (a) and marked (b) steatohepatitis with corresponding H&E stained liver biopsy sections (c and d 
respectively). Note increased diffuse lung activity at 30 min post-injection and 
hepatomegaly, plus a hint of gut activity in the left mid-abdomen, in (b). The 24 h:30 
min hepatic activity ratios were 1.2 and 3.5, respectively. Note that in (b) lung activity 
clears by 24. 
 
Fig 6. Liver biopsy microautoradiographs in SAH at 40x (a) and 100x (b) objective 
magnification demonstrating foci of parenchymal granulocyte-associated 
radioactivity, indicated by overlying clusters of black silver halide crystals, against a 
low level of background radioactivity. Corresponding gamma camera images 30 min 
(c) and 24 h (d) demonstrate a prominent increase in liver-associated radioactivity (24 
h:30 min activity ratio of 4.5). Note that in (d) lung activity clears by 24. 
 
Fig 7. Hepatic:splenic 99mTc-nanocolloid activity ratios (geometric mean of 
counts/pixel) in patients with SAH (a), abstinent cirrhotics (b) and historic normal 
controls (c) (bars depict median value, whiskers show IQR). The ratios were 
significantly lower in SAH compared with both abstinent cirrhotics and normal 
controls, consistent with severely impaired hepatic reticuloendothelial function (d).  
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